Jain Global LLC Decreases Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Jain Global LLC cut its stake in Boston Scientific by 70.5% in the third quarter, selling 153,230 shares and leaving 64,205 shares valued at about $6.27 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for roughly $15.04 million (a 10.23% reduction in his holdings), while institutional investors collectively own about 89.07% of the stock.
• Boston Scientific reported better-than-expected EPS ($0.80 vs. $0.78) and 15.9% revenue growth, but faces multiple securities class actions over its U.S. Electrophysiology disclosures—creating legal headline risk even as analysts maintain a consensus Buy rating with an average target of $108.00.

Jain Global LLC lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 70.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,205 shares of the medical equipment provider's stock after selling 153,230 shares during the quarter. Jain Global LLC's holdings in Boston Scientific were worth $6,268,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. State Street Corp increased its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Norges Bank purchased a new stake in Boston Scientific during the second quarter valued at $2,089,937,000. Invesco Ltd. lifted its holdings in Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock valued at $1,656,131,000 after acquiring an additional 111,826 shares during the period. Finally, Amundi boosted its position in Boston Scientific by 17.5% in the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider's stock worth $1,158,619,000 after purchasing an additional 1,781,830 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Up 0.9%

BSX stock opened at $69.77 on Tuesday. The business's 50-day moving average price is $81.95 and its 200-day moving average price is $92.95. The stock has a market cap of $103.53 billion, a P/E ratio of 35.96, a PEG ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. The firm's quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BSX. Royal Bank Of Canada cut their price target on Boston Scientific from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Thursday, February 5th. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a "buy" rating on the stock in a report on Thursday, February 5th. TD Cowen cut their target price on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Sanford C. Bernstein reiterated an "outperform" rating and issued a $112.00 price target on shares of Boston Scientific in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $108.00.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis arguing the stock's pullback may be overdone given solid fundamentals and recent financial results, which helps explain why investors are buying despite legal headlines. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Negative Sentiment: Multiple securities class actions and investor notices allege Boston Scientific misled investors about growth and competitive risks in its U.S. Electrophysiology segment; law firms are soliciting lead-plaintiff applicants ahead of a May 4, 2026 deadline, increasing potential litigation exposure and headline risk. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Rosen Law Firm reminder: purchasers of BSX between July 23, 2025 and Feb 3, 2026 have until May 4, 2026 to seek lead-plaintiff status in the securities fraud action — more publicity and potential consolidation of claims. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Faruqi & Faruqi issues an investor reminder about the same May 4 deadline and is investigating potential claims tied to disclosures during the Class Period — another firm adding legal resources and publicity. BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors with substantial losses about opportunities to lead a class action, repeating allegations that the company misled investors on its U.S. EP segment — amplifies potential class consolidation and damages exposure. INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
• Negative Sentiment: Several other plaintiff firms (Glancy Prongay Wolke & Rotter; Bronstein Gewirtz & Grossman; additional Rosen/Faruqi notices) have filed or circulated similar investor-alerts — increasing the odds of coordinated litigation activity and legal costs for BSX. ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.